<DOC>
	<DOCNO>NCT02612649</DOCNO>
	<brief_summary>The purpose survey evaluate safety efficacy Irribow Irribow OD Tablets post-marketing medical practice examine status treatment compliance .</brief_summary>
	<brief_title>Special Drug Use Surveillance Irribow Female Patients</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Female patient diarrheapredominant irritable bowel syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>YM060</keyword>
	<keyword>Ramosetron</keyword>
	<keyword>Survey</keyword>
</DOC>